nad+ dosage: Frequently asked questions

Increase to 500mg split twice daily. The 250mg dose falls below the plasma NAD+ elevation threshold identified in metabolic studies. Whole-blood NAD+ typically increases by fewer than 15% at this dose, which is within normal diurnal variation. The Washington University crossover trial found meaningful biomarker response started at 500mg daily, with optimal cognitive outcomes at 900mg.

You convert a high-bioavailability sublingual dose into a low-bioavailability oral dose. Sublingual absorption requires mucosal contact. Swallowing bypasses the venous route and forces NAD+ through the intestinal degradation pathway. A 200mg sublingual dose held properly delivers 30–60mg to circulation. Swallowed immediately, the same 200mg delivers 4–10mg. The dose didn't change. The route did.

Increase to 1000mg NR (500mg twice daily) and extend the trial to week 8–10 before concluding non-response. A subset of chronic fatigue patients show delayed response kinetics. Mitochondrial function improves on imaging but symptom scores lag by 4–6 additional weeks. This pattern appears more common in patients with post-viral fatigue syndromes (long COVID, post-EBV) where immune-mediated mitochondrial damage is more severe. If no objective improvement (HRV, exercise tolerance, orthostatic stability) appears by week 10 at 1000mg, NAD+ supplementation alone is insufficient. Consider stacking with CoQ10 (200–400mg ubiquinol daily) or addressing upstream factors like chronic inflammation or thyroid dysfunction.

Take the dose on an empty stomach or wait until your next fasted window. Fed-state dosing doesn't eliminate NAD+ elevation. It just prevents the NAD+/NADH ratio spike that sirtuins need. Your blood NAD+ will still rise 40–60%, but SIRT1 and SIRT3 won't upregulate because the enzyme can't access NAD+ efficiently when NADH is elevated from glucose metabolism. The 2024 trial showed zero sirtuin activation in fed-dose participants despite measurable NAD+ increases, meaning the dose raised a biomarker without engaging the pathway.

Drop to 125mg NR or 62.5mg NMN once daily with a high-fat meal, hold for 10–14 days, then escalate by 125mg every 10 days instead of weekly. Severe GI reactions during week 1 predict poor tolerance at standard titration speed. Slow escalation allows gut adaptation. Alternatively, switch to sublingual NMN, which bypasses first-pass hepatic metabolism and reduces gastric irritation. If nausea persists at any dose, the precursor formulation may contain impurities; pharmaceutical-grade synthesis eliminates filler-induced reactions.

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.